Berlin Heals appoints Dr Eric Fain as new board member
Charlie Blackie-Kelly | October 28, 2025 | Appointment | | Berlin Heals, Cardiovascular Health, chronic heart failure, medtech
Berlin Heals, a clinical-stage medical device company focused on treating chronic heart failure, has appointed Dr Eric S Fain to its Board of Directors.
Dr Fain brings over 35 years of experience in the cardiovascular sector, particularly in active implantable devices. He previously served as Group President at St Jude Medical and Abbott, where he oversaw global R&D and commercial operations for implantable cardiac devices. He currently serves as President and CEO of Procyrion, a cardiovascular-focused medical device company, and holds board positions at several other medical device companies.
Marko Bagaric, member of the Board and Co-Founder of Berlin Heals, commented: “Dr Fain’s extensive experience in cardiovascular device innovation and commercialisation will be of tremendous value as we continue to advance our Cardiac Microcurrent (C-MIC) technology toward market introduction. As we begin planning for US clinical studies and eventual submission for FDA approval, Dr Fain’s strategic insight and proven leadership will strengthen Berlin Heals’ mission to bring this groundbreaking therapy to patients suffering from heart failure worldwide.”
Berlin Heals is developing a fully implantable device that delivers a continuous electric current to a diseased heart, forming the basis of C-MIC therapy. The company reports that the minimally invasive procedure could allow patients to be discharged on the same day, reducing the treatment burden.
Dr Eric Fain commented: “Developing technology to treat heart failure is a true passion of mine and so I am honoured to join Berlin Heals at such a pivotal moment in the company’s development and strategic planning. C-MIC technology has the potential to be a true breakthrough in the treatment of these difficult to manage patients and to greatly improve patient outcomes and quality of life across the broad spectrum of chronic heart failure.”
Related Content
Prototype skin implant signals cancer by forming a visible mole
Researchers working with Professor Martin Fussenegger at the Department of Biosystems Science and Engineering at …
Could the new EU Medical Devices Regulation put the UK MedTech industry in peril?
Gill Jennings and Every’s Fiona Stevens discusses recent developments in medical devices regulation and the …
UK must prioritise $17bn medtech sector in face of Brexit, new report urges
A new report from the Institution of Mechanical Engineers (IME) has highlighted the threat Brexit …
